David Kirske - Jun 14, 2022 Form 4 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
EVP, Chief Financial Officer
Signature
David Kirske
Stock symbol
CTIC
Transactions as of
Jun 14, 2022
Transactions value $
-$45,511
Form type
4
Date filed
6/16/2022, 04:19 PM
Previous filing
Mar 11, 2022
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $9.49K +10K +135.19% $0.95 17.4K Jun 14, 2022 Direct
transaction CTIC common stock Sale -$55K -10K -57.48% $5.50 7.4K Jun 14, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -10K -2% $0.00 490K Jun 14, 2022 Common Stock 10K $0.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person.
F2 One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.